Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: A meta-analysis

N. Alipanah, A. Cattamanchi, R. Menzies, P. C. Hopewell, Richard E Chaisson, P. Nahid

Research output: Contribution to journalArticle

Abstract

SETTING: Several recent trials evaluating 4-month fluoroquinolone (FQ) containing regimens found that none of the experimental regimens were non-inferior to standard 6-month therapy in treating patients with drugsusceptible pulmonary tuberculosis (PTB). OBJECTIVE: To answer whether FQ-containing duration-shortened regimens are non-inferior to standard therapy in the treatment of patients with non-cavitary PTB. DE S IGN: Systematic review of all randomized and quasi-randomized trials that substituted an FQ into standard therapy for less than 6 months' duration to treat drug-susceptible, non-cavitary PTB. Non-inferiority was based on a 6% margin of difference. RESULTS: Of 4594 total participants in the three trials that met the inclusion criteria, 1066 patients had noncavitary disease. The pooled difference in unfavorable outcomes was 5% (95%CI 3 to 13) in patients with non-cavitary disease treated with FQ-containing regimens vs. standard therapy. In subgroup analyses, the pooled difference in unfavorable outcomes was 1% (95%CI 3 to 5) when comparing the daily form of intervention regimen with standard therapy, and 1% (95%CI 5 to 4) between regimens replacing ethambutol (EMB) with an FQ and standard therapy. No difference in risk of adverse events was noted. CONCLUSION: Daily administered 4-month regimens with substitution of EMB by an FQ may be non-inferior to standard therapy in patients with culture-confirmed, non-cavitary, drug-susceptible PTB.

Original languageEnglish (US)
Pages (from-to)1522-1528
Number of pages7
JournalInternational Journal of Tuberculosis and Lung Disease
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Fluoroquinolones
Pulmonary Tuberculosis
Meta-Analysis
Ethambutol
Therapeutics
Pharmaceutical Preparations

Keywords

  • Clinical trials
  • Gatifloxacin
  • Moxifloxacin
  • Randomized controlled trial
  • Systematic review

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens : A meta-analysis. / Alipanah, N.; Cattamanchi, A.; Menzies, R.; Hopewell, P. C.; Chaisson, Richard E; Nahid, P.

In: International Journal of Tuberculosis and Lung Disease, Vol. 20, No. 11, 01.11.2016, p. 1522-1528.

Research output: Contribution to journalArticle

@article{3de6248d366f4b1d88c04541d327f37a,
title = "Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: A meta-analysis",
abstract = "SETTING: Several recent trials evaluating 4-month fluoroquinolone (FQ) containing regimens found that none of the experimental regimens were non-inferior to standard 6-month therapy in treating patients with drugsusceptible pulmonary tuberculosis (PTB). OBJECTIVE: To answer whether FQ-containing duration-shortened regimens are non-inferior to standard therapy in the treatment of patients with non-cavitary PTB. DE S IGN: Systematic review of all randomized and quasi-randomized trials that substituted an FQ into standard therapy for less than 6 months' duration to treat drug-susceptible, non-cavitary PTB. Non-inferiority was based on a 6{\%} margin of difference. RESULTS: Of 4594 total participants in the three trials that met the inclusion criteria, 1066 patients had noncavitary disease. The pooled difference in unfavorable outcomes was 5{\%} (95{\%}CI 3 to 13) in patients with non-cavitary disease treated with FQ-containing regimens vs. standard therapy. In subgroup analyses, the pooled difference in unfavorable outcomes was 1{\%} (95{\%}CI 3 to 5) when comparing the daily form of intervention regimen with standard therapy, and 1{\%} (95{\%}CI 5 to 4) between regimens replacing ethambutol (EMB) with an FQ and standard therapy. No difference in risk of adverse events was noted. CONCLUSION: Daily administered 4-month regimens with substitution of EMB by an FQ may be non-inferior to standard therapy in patients with culture-confirmed, non-cavitary, drug-susceptible PTB.",
keywords = "Clinical trials, Gatifloxacin, Moxifloxacin, Randomized controlled trial, Systematic review",
author = "N. Alipanah and A. Cattamanchi and R. Menzies and Hopewell, {P. C.} and Chaisson, {Richard E} and P. Nahid",
year = "2016",
month = "11",
day = "1",
doi = "10.5588/ijtld.16.0217",
language = "English (US)",
volume = "20",
pages = "1522--1528",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "11",

}

TY - JOUR

T1 - Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens

T2 - A meta-analysis

AU - Alipanah, N.

AU - Cattamanchi, A.

AU - Menzies, R.

AU - Hopewell, P. C.

AU - Chaisson, Richard E

AU - Nahid, P.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - SETTING: Several recent trials evaluating 4-month fluoroquinolone (FQ) containing regimens found that none of the experimental regimens were non-inferior to standard 6-month therapy in treating patients with drugsusceptible pulmonary tuberculosis (PTB). OBJECTIVE: To answer whether FQ-containing duration-shortened regimens are non-inferior to standard therapy in the treatment of patients with non-cavitary PTB. DE S IGN: Systematic review of all randomized and quasi-randomized trials that substituted an FQ into standard therapy for less than 6 months' duration to treat drug-susceptible, non-cavitary PTB. Non-inferiority was based on a 6% margin of difference. RESULTS: Of 4594 total participants in the three trials that met the inclusion criteria, 1066 patients had noncavitary disease. The pooled difference in unfavorable outcomes was 5% (95%CI 3 to 13) in patients with non-cavitary disease treated with FQ-containing regimens vs. standard therapy. In subgroup analyses, the pooled difference in unfavorable outcomes was 1% (95%CI 3 to 5) when comparing the daily form of intervention regimen with standard therapy, and 1% (95%CI 5 to 4) between regimens replacing ethambutol (EMB) with an FQ and standard therapy. No difference in risk of adverse events was noted. CONCLUSION: Daily administered 4-month regimens with substitution of EMB by an FQ may be non-inferior to standard therapy in patients with culture-confirmed, non-cavitary, drug-susceptible PTB.

AB - SETTING: Several recent trials evaluating 4-month fluoroquinolone (FQ) containing regimens found that none of the experimental regimens were non-inferior to standard 6-month therapy in treating patients with drugsusceptible pulmonary tuberculosis (PTB). OBJECTIVE: To answer whether FQ-containing duration-shortened regimens are non-inferior to standard therapy in the treatment of patients with non-cavitary PTB. DE S IGN: Systematic review of all randomized and quasi-randomized trials that substituted an FQ into standard therapy for less than 6 months' duration to treat drug-susceptible, non-cavitary PTB. Non-inferiority was based on a 6% margin of difference. RESULTS: Of 4594 total participants in the three trials that met the inclusion criteria, 1066 patients had noncavitary disease. The pooled difference in unfavorable outcomes was 5% (95%CI 3 to 13) in patients with non-cavitary disease treated with FQ-containing regimens vs. standard therapy. In subgroup analyses, the pooled difference in unfavorable outcomes was 1% (95%CI 3 to 5) when comparing the daily form of intervention regimen with standard therapy, and 1% (95%CI 5 to 4) between regimens replacing ethambutol (EMB) with an FQ and standard therapy. No difference in risk of adverse events was noted. CONCLUSION: Daily administered 4-month regimens with substitution of EMB by an FQ may be non-inferior to standard therapy in patients with culture-confirmed, non-cavitary, drug-susceptible PTB.

KW - Clinical trials

KW - Gatifloxacin

KW - Moxifloxacin

KW - Randomized controlled trial

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84992519522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992519522&partnerID=8YFLogxK

U2 - 10.5588/ijtld.16.0217

DO - 10.5588/ijtld.16.0217

M3 - Article

C2 - 27776595

AN - SCOPUS:84992519522

VL - 20

SP - 1522

EP - 1528

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 11

ER -